This book will be sought out by women wishing to know more about Evista, Eli Lilly's trade name for raloxifene, which received FDA approval in January 1998 for the prevention of osteoporosis. Goldstein, a member of the advisory board for the team that developed raloxifene, and Ashner, a journalist and therapist, provide help in assessing the benefits and side effects of this new therapy, which benefits bones and lipid profile while significantly reducing the risk of breast cancer linked to traditional hormone replacement therapy (HRT). The authors emphasize that raloxifene and other SERMs (estrogen substitutes) are approved for use by postmenopausal women. HRT remains the treatment of choice for hot flashes and other symptoms experienced during menopause; postmenopausal women can benefit from raloxifene, which acts like estrogen in the bones and cardiovascular tissues but not in the reproductive system. For those who choose not to take estrogens during menopause, the authors offer suggestions for coping with symptoms. Recommended.?Jodith Janes, Cleveland Clinic Foundation
Copyright 1998 Reed Business Information, Inc.
Book Description
Most women know the benefits of estrogen replacement after menopause: It reduces the risk of osteoporosis, heart disease, even Alzheimer's disease. Many are still reluctant to take it, because it increases the incidence of breast and uterine cancer. But there is a revolution occurring in hormone replacement therapy. Synthetic hormones, Selective Estrogen Receptor Modulators (SERMs) can give women the benefits of estrogen without the risks. And The Estrogen Alternative is the first book to discuss how the latest advances in this field will dramatically improve women's health. Written by Steven R. Goldstein, M.D., a world-renowned obstetrician and gynecologist, and Laurie Ashner, a prominent journalist and therapist, The Estrogen Alternative will answer the questions women have about traditional estrogen therapy, herbal estrogen therapy, SERMs, and arm readers with information they need to have when they consult their doctors. A member of the advisory panel for the team that developed Raloxifene, one of the first SERMs to garner FDA approval, Dr. Goldstein is uniquely qualified to advise women on the cutting-edge of hormone replacement therapy. He discusses the subject in the way every woman wishes her own doctor would, and shows the remarkable strides medicine is making. The Estrogen Alternative is a resource every woman can use to help maintain good health in the second half of her life.
See all Editorial Reviews
